Tachycardia is a known adverse effect during clozapine treatment. However, prevalence reported differs widely between studies and hitherto there are no studies comparing clozapine-treated patients with a similar control group. The present study was carried out to assess the prevalence of tachycardia in patients treated with clozapine and antipsychotic long-acting injections (LAI). Data on heart rate (HR), concomitant medication, and relevant anthropometric and laboratory measurements were collected for all clozapine-treated patients (n=174) in a defined catchment area and compared with data on patients treated with LAI (n=87). In total, 33% of patients on long-term clozapine treatment had tachycardia (HR>100) compared with 16% in the LAI group (P<0.001). The mean HR was 91 in the clozapine group and 82 in the LAI group (P<0.001). Clozapine dose correlated with HR. The majority of patients with HR more than 100 received no specific treatment for tachycardia. In conclusion, the prevalence of tachycardia was twice as high in patients treated with clozapine as in a similar patient group with severe schizophrenia spectrum disorder. The tachycardia was in many cases clinically unnoticed. Tachycardia during antipsychotic treatment is a common phenomenon that must be monitored for actively and, when noticed, further investigated and treated.

中文翻译：

---

氯氮平与抗精神病药长效注射治疗的心动过速。

心动过速是氯氮平治疗期间的已知不良反应。但是，报道的患病率在不同研究之间差异很大，迄今为止，尚无将氯氮平治疗的患者与相似的对照组进行比较的研究。本研究旨在评估接受氯氮平和抗精神病长效注射剂（LAI）治疗的患者的心动过速患病率。在定义的集水区收集了所有接受氯氮平治疗的患者（n = 174）的心率（HR），伴随用药以及相关的人体测量学和实验室测量数据，并与接受LAI治疗的患者（n = 87）进行了比较。总的来说，长期接受氯氮平治疗的患者中有33％患有心动过速（HR> 100），而LAI组则为16％（P <0.001）。氯氮平组的平均HR为91，LAI组的平均HR为82（P <0.001）。氯氮平剂量与HR相关。HR大于100的大多数患者未接受针对心动过速的特殊治疗。总之，用氯氮平治疗的患者的心动过速患病率是严重精神分裂症谱系障碍相似患者组的两倍。在许多情况下，心动过速在临床上并未引起注意。抗精神病药治疗期间的心动过速是一种常见现象，必须对其进行积极监测，发现后应进一步研究和治疗。在许多情况下，心动过速在临床上并未引起注意。抗精神病药治疗期间的心动过速是一种常见现象，必须对其进行积极监测，发现后应进一步研究和治疗。在许多情况下，心动过速在临床上并未引起注意。抗精神病药治疗期间的心动过速是一种常见现象，必须对其进行积极监测，发现后应进一步研究和治疗。